Welcome to BINOSTO

Strengthen your bones with Binosto (alendronate sodium) effervescent tablet for oral solution 70 mg

The only once-weekly effervescent bisphosphonate with 4 buffering agents for the treatment of osteoporosis in postmenopausal women and treatment to increase bone mass in men with osteoporosis.

Important limitations of use: Optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.

Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

How do you feel about taking pills? See what an NOF* survey found!
*National Osteoporosis Foundation

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Click me, it will be preserved!

If you try to open a new ColorBox while it is already open, it will update itself with the new content.

Updating Content Example:
Click here to load new content